Sugi Predict

Sugi Predict / Compounds / SCHEMBL7950972

SCHEMBL7950972

SCHEMBL7950972

O=C(Cc1ccc(F)cc1)Nc1n[nH]c2nc(-c3cnn4ccccc34)c(F)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.43
▸ AXL P30530 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CDK2 P24941 7/20 0.41
▸ CDK1 P06493 2/20 0.41
▸ CDK4 P11802 1/20 0.41
▸ MAPK14 Q16539 1/20 0.39
▸ MET P08581 1/20 0.37
▸ IRAK4 Q9NWZ3 1/20 0.37
▸ GSK3A P49840 2/20 0.37
▸ GSK3B P49841 2/20 0.37
▸ MAP4K4 O95819 1/20 0.37
▸ LIMK1 P53667 1/20 0.37
▸ CDK5 Q00535 1/20 0.37
▸ DYRK1A Q13627 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13099704 0.87 CDK2 (0.42) KDM4ENPC1ALDH1A1HTTRAB9A
SCHEMBL13099651 0.86 CDK1 (0.40) MAPK1AXLKDM4EALDH1A1SMN1; SMN2
SCHEMBL3261020 0.85 MAPK1 (0.43) MAPK1KDM4ENPC1ALDH1A1RAB9A
SCHEMBL13099662 0.83 IRAK4 (0.45) KDM4ENPC1ALDH1A1HTTRAB9A
SCHEMBL8043054 0.82 EPHB3 (0.47) KDM4ENPC1ALDH1A1HTTRAB9A
SCHEMBL8031088 0.82 CDK2 (0.41) MAPK1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL13099726 0.82 EGFR (0.39) MAPK1HTTCDK2CDK1IRAK4
SCHEMBL8043843 0.81 GSK3A (0.58) CDK2GSK3AGSK3B
SCHEMBL7954533 0.81 AXL (0.40) MAPK1AXLKDM4ENPC1ALDH1A1
SCHEMBL8048684 0.81 ROCK1 (0.46) KDM4ENPC1ALDH1A1HTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 — — US disclosed
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 — — US disclosed
WO-2010027114-A1 USE OF PYRAZOLE-PYRIDINE DERIVATIVES AND ITS SALTS FOR TREATING OR REVENTIN OSTEOPOROSIS CHOONGWAE PHARMA CORPORATION (KR) 2010-03-11 — — WO disclosed
WO-2009038385-A2 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2009-03-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME MAP3K20, MAP3K3, MAP3K1 MAPK1 164/4885AXL 955/4885KDM4E 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.